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1. Introduction  
Cholera is an acute enteric infection, with huge pandemic potential, caused by ingestion of 
food or water contaminated with the bacterium Vibrio cholerae, the gram negative bacteria 
(Sack, Sack et al. 2004). The etiologic agent responsible for cholera was identified in 1883 
when Robert Koch demonstrated that comma(-shaped) bacteria, later designated as V. 
cholerae, causes cholera infection (Koch 1884). Since Koch's discovery of cholera virulent 
factor, different specific strain variants of V. cholerae have been identified. For the majority of 
cholera's disease outbreaks two biotypes of V. cholerae'sserogroup O1 are responsible: 
Clasical and “El Tor”, as well serogroup O139 that was responsible for a large epidemic in 
Bangladesh and India (Ramamurthy, Garg et al. 1993). Non-O1 and non-O139 V. cholerae can 
cause mild diarrhoea but do not generate epidemics (Ramamurthy, Bag et al. 1993). Cholera 
transmission is closely related to inadequate environmental conditions that can be find in 
suburban slums where the basic infrastructure is not available, as well as in camps for 
internally displaced people or refugees, where minimum requirements of clean water and 
sanitation are not met. A typical example of such non-promising situation has induced an 
outbreak of Cholera after earthquake in Haiti in January 2010 (Andrews and Basu 2011). The 
short incubation period of two hours to five days, enhances the potentially explosive pattern 
of outbreaks. Intensive efforts for the identification of the basis of Cholera disease at a 
molecular level were done by different research groups during the 1960s, until Finkelstein 
and co-workers recognized a protein toxin as a major virulent factor that causes the massive 
fluid release in Cholera infection (Finkelstein, Atthasampunna et al. 1966). The efforts to 
solve a complete structure of Cholera toxin by X-ray diffraction analysis were concluded 
during the 1990s (Spangler 1992; Zhang, Scott et al. 1995). Up to date, 27 X-ray structures 
related to Cholera toxin (CT) are deposited in the Protein Databank.  The structure and 
function of CT at the molecular level will be the subject of our review. In this work we will 
also show some examples of structure based design of various types of CT inhibitors; we 
will introduce catechin-like compounds as inhibitors of the enzymatic A unit of CT; mimics 
of oGM1 as inhibitors of the non-toxic pentamer of B subunits of CT (CTB); as well as 
multivalent inhibitors that very effectively prevent adhesion of CTB to GM1 receptors at the 
surface of epithelial cells. At the end, we will also describe a new strategy for developing 
inhibitors via targeting binding site for blood group antigens in Cholera Toxin. 
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2. Cholera toxin – structure and mode of action 
Cholera toxin (CT) belongs to the family of AB5 bacterial toxins, which includes CT itself 
and the Escherichia coli heat-labile toxins (LTs) LT-I and LT-II, among others. This family of 
bacterial toxins is named after the characteristic architecture comprising a single 
catalytically active component, A, and a non-toxic pentamer of B subunits (B5) (Fig. 1a). The 
structure and function of AB5 toxins have been reviewed in detail on several occasions 
(Bernardi, Podlipnik et al. 2006; Hol, Fan et al. 2004; Hayes, Turnbull 2011).  
 
Fig. 1. (A) Holotoxin CT and (B) pentamer B complexed with oGM1. 
The A subunit of CT is composed of two distinct parts A1 and A2. The A1 component is 
responsible for the toxic enzyme activity, while the A2 component serves as non-covalent 
linker of subunit A to subunit B. Each of five CT's B-subunits is composed from two Ǐ 
helices and two three-stranded ǐ sheets, that form together a doughnut-shaped structure, 
which has a central pore into which the C-terminal of A2 subunit extends. The B pentamer is 
responsible for binding CT to ganglioside GM1 on the external membrane of intestinal 
epithelial cells. This binding is recognized as a key event for initiation of the threatening 
action of CT. The interaction of the oligosaccharidic head groups of ganglioside GM1 
(Galǐ1-3GalNAcǐ1-4(NeuAcǏ2-3)Galǐ1-4Glcǐ1-OH,oGM1) with B5 unit of CT is depicted in 
Fig. 1b. It is interesting that the binding ability of the B-pentamer to cell surface receptors is 
retained even in absence of the A-subunit. However, the complete AB5 holotoxin is needed 
for actual intoxication.  
The B pentamer of CT (CTB) interacts with the soluble, monovalent oligosaccharide portion 
of GM1 (oGM1) with strong affinity, the binding process is weakly cooperative. The close 
view of the interaction based on 1.25 Å resolution structure of oGM1:CTB complex (Merritt, 
Sarfaty et al. 1994) is shown in Fig 2b. We may observe that branched oGM1 (Fig 3) is 
attached to CTB binding site with two fingers: the first one is a sialic acid “thumb” and the 
second one a GalB(1->3)GalNAc “forefinger” (two-fingered grip). Most of the contacts are 
given by the “finger” tips: in terms of buried protein surface, the terminal Gal and Neu5Ac 
residues contribute 39% and 43%, the rest and minor part of protein surface is buried with 
GalNAc. The most recent value of the dissociation constant for interaction between one 
oGM1 and one CTB binding site has been evaluated by Isothermal Titration Calorimetry 
(ITC) and it was found to be 43 nM (Turnbull, Precious et al. 2004), this is one of the 
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strongest known protein-carbohydrate interaction. It has been also observed that all of the 
mono- or disaccharide fragments of oGM1 bind to CTB much more weakly; for example, the 
terminal galactose residue displays Kd=15 mM, which is in the case of the Gal-GalNAc 
forefinger improved by only a factor of two. 
 
Fig. 2. (A) Structure of ganglioside head groups. (B) Close view of CTB:oGM1 interaction. 
The other important binding determinant, Neu5Ac, binds even more weakly to the protein (Kd 
≈ 200 mM). The analysis of results obtained by dissecting of the oGM1:CTB interaction by ITC 
has shown that high affinity and selectivity of oGM1:CTB interaction originates mainly from 
the conformational pre-organisation of the branched GM1 pentasaccharide rather than 
through the effect of cooperativity of terminal moieties galactose and sialic acid. The terminal 
galactose residue in the “forefinger” binds to the CTB binding site very specifically. The 
pyranose ring of this galactose is stacked on top of Trp88 (CH/pi interaction) and forms an 
extensive hydrogen bond network involving Asn90, Lys91, Glu51 and Gln61 residues from 
CTB5. The terminal galactose is docked in a deep cavity that is shielded from the solvent, on 
the other hand the rest of the toxin's binding site is shallow and solvent exposed. The sialic 
acid (Neu5Ac) represents the second important moiety of GM1 required for recognition of 
Cholera toxin. The sugar ring of sialic acid makes hydrophobic interaction with Tyr12, 
whereas hydroxyl, and N-acetyl substituents form hydrogen bonds with CTB residues, while 
carboxyl group forms water-mediated hydrogen bond with Trp88. 
The action of CT is initiated by binding of CT via the B5 pentamer to GM1s receptors that are 
part of the external membrane of intestinal epithelial cells. When CT binds to the cell, the 
whole toxin is transferred into the cell via receptor-mediated endocytosis. The toxin is then 
transported to the endoplasmic reticulum (ER), where A subunit dissociates from the rest of 
the protein assembly. Subunit A is then split to subunits A1 and A2 by peptide-disulfide 
isomerase in the ER. Subunit A1 is then translocated to the cytosol of the host cell, where it 
catalyses the covalent transfer of an ADP-ribose moiety from NAD+ to Arg201 of the 
signalling protein GsǏ (a component of an adenylate cyclase system). Adenylate cyclase 
system is normally activated by a regulatory protein Gs and GTP; however the activation is 
normally brief, because another regulatory protein (Gi) hydrolyses GTP. The normal 
situation is described in Fig 3a. Cholera toxin catalyses transfer of ADP to adenyl cyclase 
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cycle. Ribosylated form of Gs stabilizes the GTP bound form of protein, which stays 
continually activated (Cassel and Pfeuffer 1978). This situation is shown in Fig 3b.  
 
Fig. 3. Action of enzymatic unit of Cholera Toxin. (A) Normal action. (B) Permanent 
activation of Adenylate cyclase system. 
This modification of the adenylate cyclase system results in an elevated level of AMP which 
causes the activation of the sodium pumps in the lumen of the cells through an AMP-
dependent kinase pathway, forcing the Na+ ions out. The electrochemical imbalance is then 
compensated by driving Cl- and H2O out of the cells. The process of Cholera Toxin action is 
followed by enormous loss of water from the epithelial cells into the intestinal lumen, 
causing water diarrhoea characteristic for cholera.  
It has been shown that A1 by itself has relatively low enzymatic activity in vitro. The 
interaction of A1 with ADP-ribosylation factor (ARF) protein from human host increases the 
enzymatic activity of A1. Numerous studies in vitro and in vivo have indicated the importance 
of tight interaction between A1 fragment and ARF. Recent structural investigations of a CTA1 
:ARF6-GTP complex pointed out that binding of ARF6-GTP causes dramatic changes in the 
CTA1 loop regions that open the binding site for NAD+ (Hol, O’Neal et al. 2005). 
Taking into account structural information and given mechanism of action of CT, three 
different strategies are possible to design a prophylactic cure against Cholera: 
 Inhibition of the action of the catalytically active unit A of CT. 
 Design of small molecules that act as a decoys for the toxin's GM1 binding site and thus 
prevent adhesion of CT to cell membranes of epithelial cells. 
 Prevention of assembly of AB5 complex that takes place in the cytosol. 
In further writing, the first two strategies of the development the Cholera toxin inhibitors 
will be reviewed, with special attention to experience based on our recent work in this field 
of medicinal chemistry.  
3. Natural products as Cholera toxin inhibitors 
During the history, traditional healers have prepared medicaments for the treatment 
(prevention) of Cholera infections from various medicinal plants. The most common ways to 
administer such natural remedies are infusions or decoctions that are usually compositions 
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of numerous natural products. The active substances from medicinal plants can treat 
Cholera via different pharmacological mechanisms; from the direct antimicrobial against V. 
cholerae, prevention of adhesion of CT to the GM1 receptors at surface of epithelial cells, to 
direct inhibition of ADP-ribosylation of active unit of CT. The improved understanding of 
the CT toxicity at the molecular level and the further set up of modern biological assays, has 
allowed in recent years the identification of different classes of bioactive natural products. 
An important class of such products are polyphenols from green and black tea, green 
apples, hop bract and the Chinese rhubarb rhizome. Garlic extract is another example of 
traditional cure against diarrhoea diseases such as cholera. Recent researches have 
recognized a galactan polysaccharide as a major anti-choleric component of garlic (Politi, 
Alvaro-Blanco et al. 2006). Some interesting natural inhibitors of CT are shown in Fig 4. 
Toda et al. (1992) reported that polyphenol catechins (EGC, 3, ECG, 4, and EGCG, 5) isolated 
from green tea have protective function against infection with V. cholerae O1. EGCG and 
ECG also protect against hemolysin (another toxin from V. cholerae that causes red blood cell 
rupture) in a dose dependent manner–the more green tea catechins, the better the 
protection. Animal studies also showed that these catechins reduced the fluid accumulation 
(the primary cause of cholera fatality) from CT (Toda, Okubo et al. 1992). 
Toda et al. (1991) have also suggested that extracts of black tea have anti-bactericidal 
function against V. cholerae O1. The major active components of black tea that could be 
responsible for protective activity against V. cholerae O1 are theaflavin-3,3'-digallate, 9 and 
thearubigin, 10.  
Saito et al. (2002) have shown the anti-choleric activity of natural polyphenols extracted from 
immature apples. They described that the inhibitory effect of apple polyphenols extract 
(APE) on CT-catalyzed ADP-ribosylation of agmantine is dose-dependent and it is due to 
the inhibition of the enzymatic activity of the A subunit of CT. The concentration of APE at 
which 50% of the enzymatic activity of CT (15 μg/ml) is inhibited was approximately 8.7 
μg/ml. Bioassay oriented fractionation of APE indicated that the highly polymerized 
catechins, also named procyanidine polymers, are the major inhibitory components of this 
apple extract. Other constituents like the non-catechin-type polyphenols (chlorogenic acid, 
phloridzin, phloretin, caffeic acid, and p-coumaric acid) and the monomeric catechins 
(catechin and epicatechin) have shown week inhibitory activity. The results indicate that 
APE disturbs the biological activity of CT in vivo, also but not only via inhibition of the 
enzymatic activity of A-subunit. An additional explanation for the in vivo reduction of 
secretory activity of APE can also be the protection of the intestine's mucosa with 
polymerized catechins. Procyanidins B1, 6, C2, 7 and tetracatechin, 8 representative 
structures from Saito study are shown in Fig. 4. 
Hor et al. (1995) also reported in vivo CTA inhibitory activity of proantho-cyanidines 
extracted from Guazuma ulimfolia, a medicinal plant used in Mexico for traditional treatment 
of diarrhoea. 
Oi et al. (2002) studied the bioactivity of rhubarb galloyl tannin (RG-tannin), a compound 
isolated from Rhei rhizome, against CT activities including ADP-ribosylation and fluid 
accumulation. This kind of heterologuos polyphenol gallate inhibits fluid accumulation in 
mouse and rabbit ileal loops that is induced by CT action, as well as catalytic activity of 
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CTA. It was also observed that RG-tannin, had no effect on the binding of CTB to the 
ganglioside GM1 or an endogenous ADP-ribosylation of membrane proteins. The authors 
prepared and tested a small library of synthetic gallates (sugar moieties esterified with 
galloyl groups) against CTA's ADP-rybosylation activity a small library of synthetic gallates. 
Some of compounds (12 for example) from their library exhibited strong inhibitory activity 
of CTAs ADP-ribosylation.  
 
Fig. 4. Structures of natural products that could serve as CT inhibitors. 
Politi et al. (2006) reported binding activity between a high molecular weight 
polysaccharide, galactan from garlic water extract and the B subunit of CT (CTB). The 
interaction was confirmed with Saturation Transfer Difference (STD) experiment, one of the 
NMR methods used to measure interaction between ligands and target receptor, and with 
fluorometric binding assays. This study indicates that one galactan polymer could bind with 
large number of CTB protein monomers. The ability of galactan to form high molecular 
weight aggregates with CTB and thus prevent adhesion to cell-surface could be the main 
reason for its inhibitory activity. A fragment of galactan 13 is shown in Fig. 4.  
Podlipnik (2009) has collected polyphenol structures from different sources and described a 
structure-based model of inhibition of ADP-ribosyltransferase activity of Cholera toxin by 
polyphenol's. Compounds 1-12 (Fig 4) are members of the polyphenol´s library used for 
virtual screening against CTA1 . For docking purposes a model based on a crystallographic 
structure of CTA1:ARF6-GTP complex (Hol, O'Neal et al. 2005) was prepared. From docking 
(Glide XP) results it is evident that mono catechines can penetrate deeply into the binding 
site of CTA (Fig. 5a). The inhibitory activity of polyphenols generally increases with their 
complexity, measured by number of hydroxyl groups attached to the scaffold. On the other 
www.intechopen.com
 Structure Based Design of Cholera Toxin Antagonists 
 
183 
hand, oligocatechins can not penetrate into the binding site in the whole extension, such 
compounds could additionally form numerous non-specific contacts with the protein 
surface, and hinder NAD+ to access the binding site (Fig. 5c). Nice fits to CTA binding site 
have been also observed for theaflavin-3,3 digallate (Fig. 5d), 9 from black tea and Oi's 
synthetic gallate (Fig. 5b), 12, the results of molecular docking (Glide XP) indicate that these 
two compounds could act as strong inhibitors of CT´s ADP-ribosylation activity . 
 
Fig. 5. Docking poses (GlideXP) for selected polyphenols. (A) epigallocatechin gallate; (B) 
1,2,3,6-tetra-O-galloyl-D-glucose; (C) tetrameric catechin; (D) theaflavin-3,3-digalate. Yellow 
coloured NAD+ is appeared in each CTA:ligand complex as a reference. 
Many other plants have been used for centuries around the world in traditional medicine as 
natural remedies for cholera and other diarrhoeal infections. Most of the current 
pharmacological studies are oriented to test antibacterial activity of some of these medicinal 
species from plant extracts against V. Cholerae. On the other hand, direct investigations of 
natural products as potential CT inhibitors are very rare, this field of research is still open 
and some additional founding of direct biological action of natural compounds to cholera 
toxin and other AB5 toxins are more than welcome.  
4. Rational design of GM1 mimics as Cholera toxin inhibitors 
The synthesis of ganglioside GM1 itself is very complex (Sugimoto, Numata et al. 1986), 
therefore one of the strategies how to prevent adhesion of CTB to the cell surface involves 
design and synthesis of functional and structural mimics of oGM1 (Fig 6).  
NMR and theoretical studies of the conformational behavior of GM1 and of other 
ganglioside head groups (e.g. GM2, GM3, and asialo GM1) have shown that the 3,4-
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branching at Gal-II residue is the main reason for rigidity of oGM1 structure, so Gal-II 
residue appears to act as the scaffold that holds together the two terminal Gal-IV and 
Neu5Ac moieties at the proper orientation for optimal interaction with CT (Bernardi and 
Raimondi 1995; Bernardi, Arosio et al. 2002). Bernardi et al. have used the above structural 
hypothesis to develop and design ligands (14 for example) using conformationally restricted 
cis-1,2-cyclohexanediol, 15, as a replacement of Gal-II residue in oGM1 (Bernardi, Checchia 
et al. 1999; Bernardi, Arosio et al. 2001). The experimental results obtained by ELISA assays 
and fluorescence titration have shown that CT inhibition activities of Bernardi's mimics and 
oGM1 are more or less in the same range. The major problem in the synthesis of the “first 
generation” of the Bernardi's mimics is the stereoselective syalilation of cis-1,2-
cyclohexanediol, this step represents the bottleneck of the synthesis. Therefore, a further 
simplification of oGM1 structure that has been based on the replacement of the sialic acid 
residue with simple Ǐ-hydroxyl acids, 16-20 was proposed by Bernardi's research group 
(Bernardi, Carrettoni et al. 2000).  
 
Fig. 6. Structures of Bernardi's GM1 mimics. 
 
Fig. 7. Poses (Glide XP) of Bernardi's GM1 mimics: (A) 18 and (B) 20 to CTB . 
The next widely used approach to design CTB inhibitors is to use the terminal galactose as 
an anchor to which various pharmacophores can be attached. Minke et al. (1999) have used 
fluorescence titrations and ELISA assays to screen a series of commercially available 
galactose derivates. The most active compound from this series was meta nitrophenyl Ǐ-D-
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galactoside (MNPG), 21. Its affinity for CTB (IC50 = 720 μM) is two orders of magnitude 
higher than it is found for galactose. (Minke, Roach et al. 1999) (Fan, Merritt et al. 2001) 
Further crystallographic studies have shown the displacement of a water molecule that is 
structurally bound to CTB by the meta nitro group of the MNPG's phenyl ring. The 
mentioned displacement leads to an increase in the entropy of the system and creates tight 
hydrogen bond interactions between the nitro group of MNPG and CTB could, which may 
be the reason for an increased CT inhibitory activity (Fan, Merritt et al. 2001). It has been 
also observed that m-carboyxphenyl Ǐ-D-galactoside (MCPG), 22, binds to the target with a 
different binding mode. Poses of MCPG and MNPG extracted from crystallographic 
structures are shown in Figs. 9a and 9b, respectively (Fan, Merritt et al. 2001).  
 
Fig. 8. Some examples from MNPG (MCPG) library. 
 
Fig. 9. Poses of (A) MNPG, 21 and (B) MCPG, 22 to CTB. Poses are extracted from 
crystallographic data.  
Fan et al. designed a library of CTB antagonists where rigid hydrophobic rings were linked 
with different short and flexible aliphatic linkers to the meta position of phenyl ring of Ǐ-D-
galactoside (Fan, Pickens et al. 2002). Some compounds from the mentioned libraries are 
shown in Fig. 9. This modification of MNPG allows to explore different regions of CTB 
binding site. Minke et al. (1999) explored a hydrophobic pocket in the bottom of the LT-II 
binding with series of galactosides that have large hydrophobic moieties, and found that 
compound 24 had the lowest IC50=40 μM, which is more than three orders of magnitude 
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lower from the IC50 of galactose . Docking (Glide XP) pose of 24, an Ǐ galactoside with large 
rigid hydrophobic moiety, to CT is shown in Fig. 12a.  
Pieters et al. (2001; 2002) synthesized monovalent lactose-derived ligands for Cholera toxin, 
an example of such ligand is 25, where a thiourea moiety served as a spacer between lactose 
and aromatic system. A 72 fold enhancement of binding affinity of the compound 25 
(Kd=248 μM) versus lactose (Kd=18 mM) to CTB determined by fluorescence titration was 
observed. The next step to improve Pieters' ligands was to increase the rigidity of a spacer 
between the lactose and a aryl group. The fluorescence study of 26 (Kd=23 μM) revealed one 
order of magnitude enhancement in the affinity of 25 for the CTB. Two examples from the 
library of Pieters' ligands based on lactose scaffold are shown in Fig. 10. 
 
Fig. 10. Pieters' lactose derived ligands. 
Mari et al. (2004; 2006) designed and synthesized a galactose-derived bi-cyclic scaffold, the rigid 
framework and possibility of functionalization at appended side-chain made these compounds 
interesting for further combinatorial development. NMR and conformational search analysis 
showed, however, that these compounds were more flexible than expected and did not fit the 
cholera toxin's binding site. An example, 27 from their library is shown in Fig. 11.  
 
Fig. 11. Cholera toxin inhibitors: bi-cyclic inhibitor, 27 and cinnamic acid galactoconjugates 
28-33. 
Podlipnik et al. (2007) designed a small focused library of functionalized C-galactosides that 
could serve as non-hydolysable inhibitors of Cholera toxin. The fact that C-galactoside 
anchors (compound 28 from Fig. 11) can be synthesized in a few steps from galactose, thus 
avoiding the need for protecting groups, and their metabolical stability are the main reasons 
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for the selection of the scaffold. The approach that has been adopted to identify CT 
inhibitors involves the following steps: the development and validation of a 
docking/scoring protocol based on a set of known pseudo-GM1 ligands; the design of a 
focused library of C-galactosides; the synthesis and affinity evaluation (by SPR) of selected 
elements of the library. The authors have tried to design relatively rigid ligands with Ǐ 
configuration on Galactose anomeric center that could fit CTB binding site. Cinnamic acids 
and their derivatives have been found as an ideal solution for conjugation functionalized C-
galactosides (compounds 29-33 from Fig. 11). The best value of IC50 (125 μM) has been 
observed for compound 30. The pose of this compound within CTB binding site (Glide XP 
docking) is shown in Fig. 12b.  
 
Fig. 12. Docking (Glide XP) poses of (A) Verlinde's ligand 24 and ligand 30 from cinnamic 
acid galactoconjugates library to CTB. Comparison of two galactoconjugates with  
configuration on anomeric centre. 
 
Fig. 13. General scheme for design of non-hydrolysabile Cheshev's bidentate CT inhibitors. 
Cheshev et al. (2010) have used click chemistry to design a library of non-hydrolyzable 
bidentate CTB ligand, where two binding determinants, galactose and sialic acid, are 
connected to one other as they are in oGM1. All compounds from their library were 
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synthesized from readily available precursors using high performance reactions, including 
click chemistry protocols, and avoiding glycosidic bonds. The general strategy of Cheshev's 
design is shown in Fig. 13. The affinity of bidentate ligands to CT measured by weak affinity 
chromatography could be enhanced up to one or two orders of magnitude relative to the 
individual pharmacological sugar residues. A further enhancement of CT inhibition could 
be accessed by conjugation of some of the compounds from the library with polyvalent 
aglycons. Two examples from Cheshev's library are shown in figure 14. Nice fit computed 
with Glide XP docking software of R-epimeric form of ligand 34 to CTB is shown in Fig. 14.  
 
Fig. 14. Two examples from Cheshev´s design and docking (Glide XP) pose of R epimer of 
compound 35 to CTB.  
In this section we shortly described a rational design of CTB antagonists derived from 
structural simplification of oGM1 – the natural receptor for CT. The presented structures are 
in the range of very close structurally related mimics of oGM1, such as psGM1, 14 and Ǐ-
hydroxylacid derivatives, 16-20 with Kd that is close to value found for oGM1 itself, to very 
simple galactoconjugates MNPG, 21, cinnamic acid galactoconjugates, 29-33 for example. 
The affinity data for binding of simple galactoconjugates to CTB are still far from ideal, but 
by conjugation of these compounds with polyvalent aglycons the affinity could be enhanced 
by several orders of magnitude. The design of multivalent inhibitors will be described in 
next section of the review.  
5. Design of multivalent inhibitors 
A very effective way to enhance ligand's binding affinity toward its receptor target is to use 
the ligand in multivalent presentation. The Cholera toxin B-pentamer is an ideal target for 
studying multivalency and developing multivalent ligands against its action. Due to its high 
five-fold symmetry and the fact that it has five identical binding sites for GM1. A first 
attempt to improve oGM1 affinity using multivalency was reported by Schwarzmann et al. 
(1978), who designed and synthesized divalent oGM1 that has better affinity to CTB than 
oGM1 by itself. More recently, Schengrund et al. (1989) prepared highly active multivalent o-
GM1 ligands by linking them to a polymer (poly-L-lisine) or to a dendrimer 
(octapropyleneimine) that serves as a core.  
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Fan et al. (2002) have designed a multivalent receptor-binding antagonists against CT and LT-II 
with particular focus on exploiting the 5-fold symmetry of the binding sites on the toxin B 
pentamer. A conceptual design of such symmetric pentavalent ligand where monovalent 
“fingers” that block the toxin receptor binding site are attached to symmetric core via modular 
linker units is shown in Fig. 15. Multivalent inhibitor 36 (Fig. 16) is shown as an example of 
symmetric pentavalent inhibitor with using MNPGs as monovalent fingers. The affinity of 36 
for CTB was investigated using enzyme-linked addhesion assay, from which ED50=0.9 μM was 
determined. This represents more than 250-fold enhancement of the activity found for MNPG, 
21. Crystallographic studies of complex between 36 and CTB brought additional support for a 
1:1 association model between the ligand and the toxin, the canonical water is displaced also in 
this case (Minke, Pickens et al. 2000; Hol, Zhang et al. 2002). 
 
Fig. 15. General scheme of Fan's symmetric multivalent inhibitor design.  
 
Fig. 16. An example of multivalent inhibitor with pent-fold symmetry designed by Fan. 
Another strategy for the design of multivalent inhibitors involves the use of dendrimers. A 
typical example of such design was shown by Pieters and cooworkers (Pieters, Vrasidas, et 
al. 2001; Pieters, Vrasidas, et al. 2002), who derived denrimers from 3,5-di-(2-
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aminoethoxy)benzoic acid repeating units with 2,4 and 8 end groups to which lactose 
isothiocyanate units, 25, were attached, providing thioureea-linked glycodendrimers 37 (Fig. 
17). Analysis of fluorescence titration data showed that the affinity of these compounds for 
CT was increased by one order of magnitude relative to the monovalent ligands. It has been 
also shown that the branching of dendrimer provided only a modest increase in the potency 
of the ligand. The authors have also reported same indications that ligands are able to bind 
to multiple toxin molecules, rather than to single B pentamer.  
 
Fig. 17. A scheme of Pieters' multivalent inhibitor based on dendridic structure. 
A further improvement of multivalent ligand's affinity for the toxin has been obtained 
attaching Bernardi's monovalent GM1 mimic 25 to Pieters' dendrimeric core (Arosio, 
Vrasidas et al. 2004). For further improvement, the polysaccharide scaffold was provided 
with elongated spacer arms. The analysis of surface plasmon resonance data revealed 
EC50=0.5 μM for 38.  
Another option of using Bernardi's GM1 mimics for multivalent inhibitor's design has been 
presented by Bernardi, Casnati and cooworkers (Bernardi, Arosio et al. 2005). They prepared 
a bivalent ligand 39 by hooking two units of GM1 mimic 18 to a functionalized calix-[4]-
arene core. The size of affinity enhancement measured by fluorescence titration was found 
to be 3800-fold (1900-fold per sugar mimic). Recently, the huge affinity enhancement of 39 
versus 18 to CT were confirmed in our laboratory with isothermal calorimetry titration 
(Prislan, et al. 2011). 
The best known multivalent inhibitors up-to date have been reported by Pukin et al. (2007). 
In this study, GM1 containing compound was synthetized enzimatically starting from ω-
azidoundecyl lactoside, that was then coupled onto Pieters' linker-extended dendrimers by 
cooper-catalysed azide-alkyne cycloaddition. Dendrimers bearing two, four and eight GM1 
sugars were evaluated by ELISA, the IC50 values for these compounds were 2 nM, 0.2 nM 
and 50 pM, respectively. 
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Fig. 18. A scheme of multivalent Bernardi-Pieters' inhibitor based on dendridic structure and 
Bernardi-Casnati's inhibitor based on Calix-[4]-arene core. 
The most recent example of using multivalent strategy in the design of Cholera toxin 
inibitors presented in this chapter is based on the work of Tran and collaborators (Tran, 
Kitov et al. 2011). They are intensively working on designing a bidentate multivalent 
ligands. In their recent work they describe the synthesis and activities of a series of galactose 
conjugates on polyacryl amide and dextran. Nanomolar affinity of inhibitors against CT was 
obtained by conjugation of a second fragment (corresponding Neu5Ac's mimic), while 
galactose-only progenitors showed no detectable activity. The general idea of such 
inhibitor's design is shown in Fig. 19. 
 
Fig. 19. Scheme for general design of multivalent Tran-Kitov's bidentate inhibitors.  
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A variety of multivalent inhibitors were described in this chapter. Basically, the multivalent 
inhibitors are designed using linkers to connect a galactose anchor to polymeric or 
dendrimeric cores or symmetric cores (5-fold symmetry). Recently, bidentate multivalent 
inhibitors were designed with conjugation of second fragment of that corresponds to 
Neu5Ac mimic. Generally, the above results showed that strategy of designing multivalent 
presentations of monovalent ligands can bring affinity closer to what is required for 
practical application against CT.  
6. Novel binding site for blood group antigens in Cholera toxin: Potential 
target for the design of new Inhibitors? 
At the end of the 1970s, two epidemiological studies established a dependency between the 
severity of Cholera infections and the blood group phenotype (Baura, Paguio 1977; 
Chaudhuri, De 1997). In these studies it was reported that people with blood group O were 
more prone to develop severe symptoms in comparison with people of blood group A, B or 
AB phenotype. Also, it was found that this dependency is strain specific, for example, in V. 
cholerae O1 “El Tor” (responsible of the seventh (current) pandemic) and V. cholerae O139 
infections a connection with blood group phenotype of individuals was found (Glass et al. 
1985, Swerdlow et al. 1994, Farruque et al. 1994, Tacket et al. 1995, Harris et al. 2005, Harris 
et al. 2008). On the other hand, for infection with classical V. Cholerae strains, no such 
association was observed. 
The blood group phenotype of an individual is determinated by the presence or absence of 
antigenic substances on the surface of red blood cells. The ABO antigens are fucosylated 
oligosaccharide structures, carried on both glycolipids and glycoproteins. (Fig. 20) These 
antigens are not only on the surface of red blood cells, but are widely distributed 
throughout body fluids and tissues and are found also in the small intestine, the site of 
Cholera and ETEC infections. In this tissue, blood group antigens are presented on the 
intestinal epithelium cell surface (Finne 1989, Breimer 1984, Björk 1987), close to GM1 
gangliosides. Structurally, ABO antigens are very similar, the H antigen (responsible of the 
O phenotype) is a tetrasaccharide characterized by a terminal fucose residue. The A and B 
antigens are pentasaccharides with a core similar to the H antigen, but each contain and 
additional saccharide residue- a terminal 2’-N-acetyl galactosamine (GalNAc) in the A 
antigen, or a terminal galactose for the blood group B antigen. 
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Fig. 20. Schematic representation of the Blood Group antigens H, A and B. 
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Following the discovery of the relation between blood group phenotype and cholera 
susceptibility, many studies have been conducted in order to investigate the ability of 
cholera toxin and of the highly homologous heat-labile enterotoxin (LT) from 
enterotoxigenic Escherichia coli (ETEC), to recognize blood group antigens of the ABO 
system (Bennun 1989, Monferran 1990, Barra 1992, Balanzino 1994, Balanzino 1999). It has 
been hypothesized that blood group antigens, with a preference for A and B epitopes, might 
disturb the action of the toxin by interfering with binding to GM1 ganglioside in the small 
intestine. However, the well-conserved GM1 binding site of CT is believed to be 
ganglioside-specific and cannot accommodate the fucosylated blood group antigens 
according to computer modelling. Consequently, the basis for the recognition of blood 
group antigens by Cholera Toxin at a molecular level is still unclear. In a recent 
investigation, Teneberg and co-workers have discovered a novel carbohydrate binding site 
studying a chimera between the B subunits of cholera toxin and the E. coli LT. This 
CTB/LTB chimera was shown to bind blood group A or B antigens on type 2 chains 
(Ångström 2000), and was subsequently characterized in complex with a blood group A 
analogue using protein crystallography by Krengel and co-workers (Holmner 2004). The 
structure of such complex is shown in Fig 21a. A follow-up study showed that native LTB, 
despite binding blood group antigens with lower affinity, also display the same mode of 
binding as the CTB/LTB chimera (Holmner 2007). In both cases, this binding site for blood 
group ligands is clearly distinct from the primary GM1 binding site. The blood group 
recognition site is located at the interface of two B-subunits, with one of the 2 subunits 
providing the majority of the contacts to the ligand. Based on the two crystal structures, it 
was possible to explain how the toxins discriminate between different ABH epitopes. The 
GalNAc3 residue characteristic of blood group antigens binds with the toxin via several 
hydrogen bonds, including one involving its acetamido nitrogen (Fig 21b). The blood group 
B antigen is characterized by a terminal galactose residue and only differ from the A antigen 
at the 2-position, i.e. the acetamido group is replaced by a hydroxyl group. This hydroxyl 
group should preserve most of the interactions with the toxin and explains why the toxin 
does not discriminate notably between A and B epitopes. The fucose residue on the ABH 
antigens is also an important contributor to receptor recognition, however, blood group H 
determinants lack the entire terminal saccharide residue compared to blood group A and B 
determinant, and would therefore be expected to have significantly reduced binding 
affinities to cholera toxin. This assumption is substantiated by the finding that the loss of a 
single water-mediated hydrogen bond to the terminal GalNAc3 residue results in a 
pronounced decrease in binding affinity (Holmner 2004), confirming the importance of the 
terminal GalNAc residue characteristic of blood group A antigens in molecular recognition. 
All these new contributions to understand the molecular basis of the interaction between 
blood group antigens and cholera toxin were reviewed in more detail by Krengel and co-
workers (Holmner 2010). 
In conclusion, the new information on the molecular recognition of blood-group antigens 
by Cholera Toxin should encourage medicinal chemist to development improved drug 
design strategies to prepare new pharmacological agents that inactivate cholera toxin. 
Inhibitors of the interaction of the cholera toxin with its primary receptor, the GM1 
ganglioside, are especially attractive. Development of antagonists for the blood group 
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binding site of cholera toxin could enable a more effective combined therapy together 
with GM1 antagonists and, furthermore, could be used as a tool to understand the 
variability of susceptibility to Cholera infection with the blood group phenotype of 
individuals.  
 
 
 
 
 
Fig. 21. (A) A crystallographic representation of CTB/LT chimera that shows the 
comparison between the binding site of blood group A pentasaccharide analog (green 
sticks) and GM1 ganglioside (sky-blue sticks) superimposed for comparison. (B) Interactions 
between blood group A and CTB/LT chimera – close view (Holmner 2010).  
7. Methods and software 
The methodology of structure based design of CT is described in several occasions 
(Podlipnik and Bernardi 2007; Zhang 2009). Structure based design starts with preparing a 
model of the protein receptor site. Models described in our review are based on 
receptor:ligand complex. In case of exploring of A-site ligands (Section 3) we have used a 
model based on crystallographic structure of CTA1:ARF6-GTP complex (PDB-ID: 2A5F)(Hol, 
O'Neal et al. 2005). A high resolution crystallographic structure (1.25 Å) of Cholera toxin B 
pentamer complexed with oGM1 (PDB-ID:3CHB) (Merritt, Kuhn et al. 1998) has been used 
as a template for generating a model in the case of exploring GM1 mimics (Section 4). The 
raw crystallographic structures were in both cases optimized with protein preparation 
wizard provided as part of the Schrodinger Suite 2011 (http://www.schrodinger.com). The 
interaction field grids that were used for docking were centered at the center of the ligand 
www.intechopen.com
 Structure Based Design of Cholera Toxin Antagonists 
 
195 
(NAD+ in case of CT's A-Site; oGM1 in case of B-Site). All ligands described in Sections 3 
and 4 are prepared using Schrodinger's Ligprep. Glide XP (Murphy, Repasky et al. 2011) has 
been used for docking. The figures 1,2,5,7,9,12,14 and 21 representing poses were perpared 
with YASARA (http://www.yasara.com).  
8. Conclusions 
We reviewed different strategies to design an effective cure against cholera infections. The 
first strategy is based on exploring natural ligands as potential inhibitors of the ADP-
ribosylation function of CT A subunit. The data collected from various sources indicate 
that catechin derivatives found in different natural sources could limit enzymatic activity 
of CT. Maybe this is one of the major reasons why during the centuries cholera pandemies 
have spared China and Japan, the catechin-consumig countries. The second approach is to 
design mimics in a mono- and/or multivalent presentation that could bind to the GM1 
binding site in the B-pentamer, and thus prevent binding to GM1 receptors at the surface 
of epithelial cells, the first act necessary for Cholera toxin intoxication. The rational design 
of GM1 mimics is one of the most representative example of using structural information 
supported by molecular modelling methods in task to get an effective inhibitor. Nice 
examples of how multivalent presentation of single ligands can enhance affinity to CT by 
several orders of magnitude, and thus reach the levels of affinity required for practical 
applications against CT were presented. In addition we introduced a new strategy for 
developing CT inhibitors by targeting a newly identified binding site for blood group 
antigens in CT. This chapter describes examples of some successful application of 
knowledge that is connected with molecular structures and processes at the molecular 
level to design inhibitors toward Cholera toxin. The challenge to transfer the knowledge 
described in our review to achieve the practical, economic and scalable preparation of CT 
inhibitors remains still open.  
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anyone interested in promoting the health of people. Experts from different parts of the world have contributed
to this important work thereby generating this power. Key features include the history of cholera, geographical
distribution of the disease, mode of transmission, Vibrio cholerae activities, characterization of cholera toxin,
cholera antagonists and preventive measures.
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